ARS Pharmaceuticals, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | -$0.10 | -$0.10 | -$0.10 |
Q2 2024 | 0 | -$0.11 | -$0.11 | -$0.11 |
Q3 2024 | 3 | -$0.15 | -$0.13 | -$0.14 |
Q4 2024 | 0 | -$0.26 | -$0.26 | -$0.26 |
Q1 2025 | 2 | -$0.26 | -$0.26 | -$0.26 |
Q2 2025 | 2 | -$0.23 | -$0.23 | -$0.23 |
Q3 2025 | 2 | -$0.25 | -$0.25 | -$0.25 |
Q4 2025 | 2 | -$0.19 | -$0.19 | -$0.19 |
Q1 2026 | 0 | $0.02 | $0.02 | $0.02 |
Q2 2026 | 0 | $0.16 | $0.16 | $0.16 |
Q3 2026 | 0 | $0.37 | $0.37 | $0.37 |
Q4 2026 | 0 | $0.25 | $0.25 | $0.25 |
ARS Pharmaceuticals, Inc. Earnings Date And Information
ARS Pharmaceuticals, Inc. last posted its earnings results on Tuesday, August 6th, 2024. The company reported $-0.13 earnings per share for the quarter, missing analysts' consensus estimates of $-0.12 by $0.01. The company had revenue of 500,000 for the quarter and had revenue of 30,000 for the year. ARS Pharmaceuticals, Inc. has generated $-1 earnings per share over the last year ($-0.57 diluted earnings per share) and currently has a price-to-earnings ratio of -31.8. ARS Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
ARS Pharmaceuticals, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/06/2024 | Q2 2024 | -$0.12 | -$0.13 | -0.01 | $1.00 M | $500,000 |
05/09/2024 | Q1 2024 | -$0.11 | -$0.11 | 0 | $0 | |
03/21/2024 | Q4 2023 | -$0.07 | $0 | $-30,000 | ||
11/09/2023 | Q3 2023 | -$0.18 | -$0.16 | 0.02 | $0 | |
08/10/2023 | Q2 2023 | -$0.17 | -$0.18 | -0.01 | $10,000 | |
05/15/2023 | Q1 2023 | -$0.17 | -$0.12 | 0.05 | $20,000 | |
03/23/2023 | Q4 2022 | -$0.15 | $-1,316,000 | |||
09/29/2022 | Q3 2022 | -$0.07 | $189,000 | |||
08/11/2022 | Q2 2022 | -$0.48 | -$0.06 | 0.42 | $464,000 | |
03/31/2022 | Q1 2022 | -$0.08 | $663,000 | |||
03/31/2022 | Q4 2021 | -$0.67 | $754,000 | |||
09/29/2021 | Q3 2021 | -$0.65 | $528,000 | |||
06/29/2021 | Q2 2021 | -$0.70 | $2.11 M | |||
03/30/2021 | Q1 2021 | -$0.54 | $2.11 M | |||
12/29/2020 | Q4 2020 | -$0.38 | $0 |
ARS Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is ARS Pharmaceuticals, Inc.'s earnings date?
ARS Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
How can I listen to ARS Pharmaceuticals, Inc.'s earnings conference call?
The conference call for ARS Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read ARS Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for ARS Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does ARS Pharmaceuticals, Inc. generate each year?
ARS Pharmaceuticals, Inc. (:SPRY) has a recorded annual revenue of $30,000.
-
How much profit does ARS Pharmaceuticals, Inc. generate each year?
ARS Pharmaceuticals, Inc. (:SPRY) has a recorded net income of $30,000. ARS Pharmaceuticals, Inc. has generated $-0.57 earnings per share over the last four quarters.
-
What is ARS Pharmaceuticals, Inc.'s price-to-earnings ratio?
ARS Pharmaceuticals, Inc. (:SPRY) has a price-to-earnings ratio of -31.8 and price/earnings-to-growth ratio is -0.97.